Study of Immune Checkpoint Inhibitors Combined With Chemotherapy as First Treatment for Advanced and Locally Advanced Gastric Cancer

What this Trial Is About

Researchers are evaluating the effectiveness and safety of immune checkpoint inhibitors combined with chemotherapy as first-line and neoadjuvant treatments for advanced gastric cancer. This observational study also aims to investigate biomarkers to better understand how these immunotherapies work in patients with advanced or locally advanced gastric cancer. The research is sponsored by Qilu Hospital of Shandong University and focuses on outcomes important to patients receiving these therapies. Participants will receive either immune checkpoint inhibitors combined with standard chemotherapy or chemotherapy alone as part of their treatment. The study observes how these treatments perform in real-world settings without assigning treatments randomly. Researchers will monitor participants over time to collect data on survival, disease control, tumor response, and treatment side effects according to recognized assessment criteria. During the study, participants will undergo regular evaluations including scans and clinical assessments to measure overall survival, progression-free survival, disease control rate, and other outcomes up to 36 months after treatment. Safety will be monitored by tracking any adverse events related to the therapies. The study will follow participants for at least one year after the last person joins to gather comprehensive data on treatment effects and tolerability.

First-Line and Neoadjuvant Immunotherapy for Gastric Cancer